Sort   by:  
 Page size 
GenomicsPrevalent p53 gain-of-function mutants co-opt epigenetic pathways to drive cancer growth
We investigated the genomewide binding pattern of prevalent p53 gain-of-function (GOF) mutants by ChIP-seq, in a panel of breast cancer cell lines. We assessed the genomewide changes of H3K4me3 upon GOF p53 knockdown in MDA-MB-468 breast cancer cells bearing the p53 R273H mutation. This study uses C...
ORGANISM(S): Homo sapiens 
2015-07-31 | E-GEOD-59176 | biostudies-arrayexpress
TranscriptomicsMLL1 is essential for the senescence-associated secretory phenotype [RNA-Seq]
Oncogene-induced senescence (OIS) and therapy-induced senescence (TIS), while tumor-suppressive, also promote procarcinogenic effects by activating the DNA damage response (DDR), which in turn induces inflammation. This inflammatory response prominently includes an array of cytokines known as the se...
ORGANISM(S): Homo sapiens 
2016-02-23 | E-GEOD-78138 | biostudies-arrayexpress
GenomicsMLL1 is essential for the senescence-associated secretory phenotype [ChIP-Seq]
Oncogene-induced senescence (OIS) and therapy-induced senescence (TIS), while tumor-suppressive, also promote procarcinogenic effects by activating the DNA damage response (DDR), which in turn induces inflammation. This inflammatory response prominently includes an array of cytokines known as the se...
ORGANISM(S): Homo sapiens 
2016-02-23 | E-GEOD-78141 | biostudies-arrayexpress
UnknownA preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.
Not available
S-EPMC5689598 | biostudies-literature
UnknownInhibition of Upf2-Dependent Nonsense-Mediated Decay Leads to Behavioral and Neurophysiological Abnormalities by Activating the Immune Response.
Not available
S-EPMC7312756 | biostudies-literature
UnknownEffects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
Not available
S-EPMC7615589 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
Sort   by:  
 Page size